Recombinant vectors for preparation cyclic fibroblast growth factor

A recombinant expression vector produces cyclic FGF10 using intein-mediated circularization, addressing stability and half-life issues of FGFs, enhancing production efficiency and maintaining therapeutic efficacy.

KR103043478B1Active Publication Date: 2026-11-06KONKUK UNIV IND COOP CORP +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240029153
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-02-28
Filing Date
2024-02-28
Publication Date
2026-11-06
Estimated Expiration
2044-02-28

AI Technical Summary

Technical Problem

Existing fibroblast growth factors (FGFs) have short half-lives and stability issues in the body, limiting their effectiveness in therapeutic applications, and traditional methods to enhance protein stability are complex and inefficient.

Method used

Development of a recombinant expression vector that produces cyclic FGF10, utilizing a fusion protein with intein fragments to circularize FGF10, enhancing its stability and half-life through a process involving trans-splicing and optimized linker sequences.

Benefits of technology

The cyclic FGF10 exhibits increased production efficiency and stability, maintaining cell proliferation effects similar to linear FGF10 while significantly improving its half-life in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024023176627-PAT00019_ABST
    Figure 112024023176627-PAT00019_ABST
Patent Text Reader

Abstract

The present invention relates to a vector with increased production rate of FGF10 and a vector system for producing cyclic FGF10. The cyclic fibroblast growth factor 10 (FGF10) produced using a vector encoding a fragment of FGF10 or a variant thereof according to the present invention has a higher production efficiency compared to full-length FGF10. In particular, a recombinant expression vector containing a fragment of intein can cyclicize FGF10, its fragment, or its variant, which has increased stability and half-life compared to linear proteins. The cyclic FGF10 produced in this way has a cell proliferation effect similar to that of linear FGF10, while having significantly increased stability and a significantly improved half-life in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a vector with an increased production rate of FGF10 and a vector system for producing circular FGF10. Background Technology

[0002] Growth factors play an important role in regulating cell growth, proliferation, and differentiation. Therefore, our bodies possess a natural repair system for skin damage and aging caused by internal and external factors, such as injuries and surgery, and growth factors play a key role in this process. Various growth factors are produced to maintain the function of each tissue and perform their functions while being maintained at a certain concentration. As we age, the concentration of growth factors in tissues such as the skin decreases, and as cell regeneration and division functions weaken, aging progresses, leading to the formation of wrinkles and a decrease in elasticity. Among these, fibroblast growth factor (FGF) was first introduced in 1974 by Gospodarowicz (Nature, 249:123-127(1974)), and as a signaling protein that regulates a wide range of biological functions—including cell proliferation, differentiation during embryonic development, angiogenesis, regulation of nerve regeneration, and wound healing—approximately 22 types have been reported to date. The above function of fibroblast growth factor is induced through binding to the fibroblast growth factor receptor (FGFR) expressed on the cell surface. FGF is classified as belonging to a group of heparin-binding growth factors that affect the general proliferative capacity of many mesenchymal- and neuroectodermal-derived cells, including endothelial cells, smooth muscle cells, adrenal cortical cells, prostate and retinal epithelial cells, hyperdendritic glial cells, astrocytes, chronodocytes, myocytes, and osteoblasts (Burgess and Maciag, Ann. Rev. Biochem. 58:584(1989)). FGF not only induces a mitotic-promoting response that stimulates cell proliferation, but also stimulates most cell types to respond in a non-mitotic-promoting manner.These activities include promoting cell migration to the wound site (chemotaxis), initiating the formation of new blood vessels (angiogenesis), regulating nerve regeneration (neurotropism), expressing specific cell proteins, stimulating or inhibiting cell survival important in the extracellular matrix formation and healing process (Burgess, WH and Maciag, T. Ann. Rev. Biochem. 58:584-588(1989)). Along with cell growth-promoting effects, these properties provide the basis for the use of fibroblast growth factors in treatments to promote wound healing, and in the treatment of thrombosis, arteriosclerosis, etc. Therefore, FGF has been proposed to promote trauma healing (Davidson, JM, et al. J. Cell Bio. 100:1219-1227 (1985)), to minimize myocardial damage in heart disease and surgery (U.S. Patent No. 4,378,347), and to increase neuronal survival and axonal expansion (Walicke, P., et al. Proc. Nat. Acad. Sci. USA 83:3012-3016 (1986)). However, these peptide growth factors present in blood and tissues are known to have very short half-lives in the body, typically only a few minutes, and have a problem of being significantly affected by stability.

[0003] Meanwhile, proteins can be applied to various fields as biomaterials, and research is actively underway, particularly for their use as pharmaceuticals. Protein drug candidates are substances with outstanding physiological activity among proteins; they regulate biological signal transduction and function and possess distinct characteristics such as biocompatibility and in vivo specificity, allowing them to exhibit potent pharmacological effects and activity with minimal side effects and even in small amounts. It is of great significance to enhance or maintain protein activity while simultaneously promoting structural stability. Traditionally, methods have been proposed to improve stability by modifying amino acids in regions unrelated to the active site; however, this presents difficulties, such as the need to utilize highly complex design algorithms or locate the corresponding protein within a very large library of modified amino acid regions. On the other hand, some peptides found in nature possess the structure of so-called cyclic proteins, in which their amino and carboxyl terms are connected by peptide bonds; these proteins are known to have significantly higher resistance to heat, proteolytic enzymes, and denaturants compared to linear proteins. In addition, it has been revealed in several protein models that mimicking the structure of cyclic proteins found in nature exhibits higher stability compared to the corresponding linear proteins. Along with this, it has been reported that protein cyclization can have a positive effect on the refolding process of denatured proteins. As such, cyclic proteins have many advantages over general linear proteins in the development of drugs and new materials, particularly high resistance to proteases and structural stability due to restricted stereotypes. This structural rigidity of the aforementioned cyclic proteins helps to further mimic the stabilized state of folded proteins and minimize the entropy penalty associated with target binding. The problem to be solved

[0004] The objective of the present invention is to provide a circular fibroblast growth factor.

[0005] In addition, the objective of the present invention is to provide a composition for promoting cell proliferation comprising a cyclic fibroblast growth factor.

[0006] In addition, the objective of the present invention is to provide a recombinant expression vector for the production of FGF10 (fibroblast growth factor 10) with increased protein production efficiency.

[0007] In addition, the objective of the present invention is to provide a recombinant expression vector for the production of cyclic FGF10.

[0008] In addition, the object of the present invention is to provide a method for producing FGF10, a fragment thereof, or a variant thereof.

[0009] In addition, the object of the present invention is to provide a method for producing cyclic FGF10, a fragment thereof, or a variant thereof. means of solving the problem

[0010] To solve the above problem, the present invention provides a circular fibroblast growth factor.

[0011] In addition, the present invention provides a composition for promoting cell proliferation comprising the cyclic fibroblast growth factor of the present invention.

[0012] In addition, the present invention provides a recombinant expression vector comprising a sequence encoding FGF10, a fragment thereof, or a variant thereof.

[0013] In addition, the present invention provides a recombinant expression vector comprising a sequence encoding a fusion protein in which a carboxyl-terminal fragment of phosphate is fused to the amino-terminal of FGF10, a fragment thereof, or a variant thereof, and an amino-terminal fragment of phosphate is fused to the carboxyl-terminal of FGF10, a fragment thereof, or a variant thereof.

[0014] In addition, the present invention provides a method for producing FGF10, a fragment thereof, or a variant thereof.

[0015] In addition, the present invention provides a method for producing cyclic FGF10, a fragment thereof, or a variant thereof. Effects of the invention

[0016] Circular fibroblast growth factor 10 (FGF10) produced using a vector encoding a fragment of FGF10 or a variant thereof according to the present invention has a higher production efficiency compared to full-length FGF10, and in particular, a recombinant expression vector containing a fragment of intein can circulate FGF10, a fragment thereof, or a variant thereof, which has increased stability and half-life compared to linear proteins, and the circular FGF10 produced in this way has the effect of having a cell proliferation effect similar to linear FGF10, while having significantly increased stability and a significantly improved half-life in vivo. Brief explanation of the drawing

[0017] Figure 1 is a schematic diagram showing the structure of FGF10 in the entire field. Figure 2 shows the results of isolating and purifying a vector encoding the full length of FGF10 expressed in E. coli. Figure 3 shows the structure of a fragment of FGF10 and the results of isolating and purifying it by expressing a vector encoding it in E. coli. Figure 4 shows the structure of a mutant of FGF10 and the results of isolating and purifying it by expressing a vector encoding it in E. coli. Figure 5 shows a sequence in which a nucleotide sequence encoding the FGF10 protein is inserted into the vector of the present invention using BamHI and EcoRI. INTEIN_C: Npu Split integrin carboxyl terminal (C-term) fragment of DNAE; and INTEIN_N: Npu Split integrin amino terminal (N-term) fragment of DNAE. Figure 6 is a schematic diagram showing the basic configuration of a vector for producing cyclic FGF10 protein. Figure 7 is a schematic diagram showing the process of isolating integrin from a fusion protein translated from a vector encoding the cyclic FGF10 protein and producing the cyclic FGF10 protein. Figure 8 is a diagram showing a three-step process for isolating and purifying cFGF10. Figure 9 is a schematic diagram of the vector composition for producing cFGF10, the process of expressing and purifying it in E. coli, and the purified result. Figure 10 is a figure showing the composition of proteins purified by expressing the vector of the present invention in E. coli. FIG. 11 is a figure showing uncirculated full-length FGF10 (Full) and circulated FGF10 (FGF, cFGF10) produced in the basic cFGF10 protein production system of the present invention (configuration of entain C-termin-FGF10-entain N-termin), an improved cFGF10 protein production system (configuration of entain C-termin (-CGS)-linker-FGF10-linker-entain N-termin), and an optimized cFGF10 protein production system (configuration of entain C-termin (-CFN)-linker-FGF10-linker-entain N-termin). Figure 12 is a schematic diagram showing a vector in which various linkers are inserted between the target protein and the C-terminus and N-terminus. Figure 13 shows the sequence of a fusion protein produced by a cFGF10 protein production vector with optimized cyclic efficiency. Figure 14 is a schematic diagram showing the configuration of a cFGF10 protein production vector with optimized cyclic efficiency. Figure 15 is a schematic diagram showing the cyclic target protein cFGF10. Figure 16 shows the nucleotide sequence of a cFGF10 protein production vector with optimized cyclic efficiency. Figure 17 is a figure confirming the peptide binding between the N-terminus and C-terminus of cyclic FGF10 protein using the Mass spectrometry MS / MS method. Figure 18 is a figure confirming the cell proliferation activity of isolated and purified cFGF10: hFGF10-old: Protein in a state frozen at -80 degrees and thawed after final protein purification; and hFGF10-new: Protein that has never been frozen since final purification. FIG. 19 is a schematic diagram showing FGF10 constructs produced in the present invention. Specific details for implementing the invention

[0018] Hereinafter, the present invention will be described in detail with reference to the attached drawings for embodiments of the present invention. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalents interpreted therefrom.

[0019] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. Any method and material similar or equivalent to those described herein may be used in practice to test the present invention, but preferred materials and methods are described herein. Furthermore, the contents of all publications cited by reference in this specification are incorporated into the present invention.

[0021] Throughout this specification, not only are conventional one- and three-character codes for naturally occurring amino acids used, but generally accepted three-character codes for other amino acids, such as Aib (α-aminoisobutyric acid), Sar (N-methylglycine), etc., are also used. Additionally, amino acids referred to by abbreviations in this invention are described according to the IUPAC-IUB nomenclature as follows:

[0022] Alanine: A, Arginine: R, Asparagine: N, Aspartic Acid: D, Cysteine: C, Glutamic Acid: E, Glutamine: Q, Glycine: G, Histidine: H, Isoleucine: I, Leucine: L, Lysine: K, Methionine: M, Phenylalanine: F, Proline: P, Serine: S, Threonine: T, Tryptophan: W, Tyrosine: Y, and Valine: V.

[0024] In one aspect, the present invention relates to a fibroblast growth factor (FGF).

[0025] In one embodiment, the fibroblast growth factor may be fibroblast growth factor 10 (FGF10).

[0026] In one embodiment, the cyclic FGF10 fragment can be encoded by the base sequence of SEQ ID NO. 20.

[0027] In one embodiment, the cyclic fibroblast growth factor may be a cyclic protein formed by connecting both ends of a fibroblast growth factor, a fragment thereof, or a variant thereof to form a ring.

[0028] In one embodiment, the fibroblast growth factor may include any one selected from the group consisting of amino acid sequences of SEQ ID NOs 1 to 3, and the fibroblast growth factor may include any one selected from the group consisting of nucleotide sequences of SEQ ID NOs 13 to 15.

[0029] In one embodiment, the fragment of the fibroblast growth factor may include the amino acid sequence of SEQ ID NO. 4 or 5, and the fragment of the FGF10 may include the nucleotide sequence of SEQ ID NO. 16 or 17.

[0030] In one embodiment, a variant of the fibroblast growth factor may include one or more amino acid substitutions selected from the group consisting of A133C, Y177C and A199C, and the variant of the fibroblast growth factor may be encoded by any one nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID NOs 6 to 8.

[0031] In one embodiment, the recombinant expression vector of the present invention, comprising a sequence encoding a fragment of fibroblast growth factor or a variant thereof, can increase the production efficiency of fibroblast growth factor protein compared to a vector comprising a sequence encoding wild-type fibroblast growth factor.

[0032] In one embodiment, a cyclic protein having both ends of the fibroblast growth factor of the present invention, a fragment thereof, or a variant thereof connected may have an increased half-life or stability in vivo compared to a linear fibroblast growth factor, a fragment thereof, or a variant thereof.

[0033] In one embodiment, the cyclic fibroblast growth factor of the present invention may be obtained by expression and purification from a transformant transformed with a recombinant expression vector comprising a sequence encoding a fusion protein in which a carboxyl terminal (C-term) fragment of intein is fused to the amino terminal (N-term) of a fibroblast growth factor, a fragment thereof, or a variant thereof, and an amino terminal fragment of intein is fused to the carboxyl terminal of a fibroblast growth factor, a fragment thereof, or a variant thereof.

[0034] In one embodiment, the cyclic fibroblast growth factor of the present invention may be a cyclic protein formed by connecting both ends of a fibroblast growth factor, a fragment thereof, or a variant thereof, by removing an inte formed by combining an N-terminal fragment of inte and a C-terminal fragment of inte of a fusion protein translated by the recombinant expression vector.

[0035] In one embodiment, the cyclic fibroblast growth factor of the present invention can be obtained by expression and purification from a transformant transformed with a recombinant expression vector comprising a sequence encoding a fibroblast growth factor, a fusion protein in which the amino terminal (N-term) fragment of intein is fused to the amino terminal (N-term) of a fragment or variant thereof, and the amino terminal fragment of intein is fused to the carboxy terminal of a fragment or variant thereof.

[0036] In one embodiment, the intein may be a split intein, and the split intein may be a trans-splicing intein.

[0037] In one embodiment, trans-splicing requires the co-expression of both split entain fragments, namely N-entain (IN, fused with the C-termin of N-entain) and C-entain (IC, fused with the N-termin of C-entain), and trans-splicing entains belonging to the DnaE or DnaB genera corresponding to Table 1 below, such as Cfa, Npu, Ssp, Rma, Ppu, etc., may be applied, and although split entains were applied in the embodiments of the present invention, they are not limited thereto.

[0038]

[0039] When trans-intaines are expressed, they are expressed in separate forms, but when the N-terminal domain (Int-C) and the C-terminal domain (Int-N) meet and combine to form a single complete intain complex, the intain complex is spliced ​​and detached. At this time, the exteins (fibroblast growth factor, its fragments, or its variants) located on the outer periphery of the intain complex are connected by peptide bonds to form a single protein (Fig. 7).

[0040] In the present invention, intein refers to a region that is cleaved off during the protein splicing process, a post-translational process in which a portion of the protein precursor is removed before the protein folds into its finished form. It is known that in some proteins, a portion of the precursor protein is cleaved off by an autocatalytic reaction after translation, while the remaining portion recombines to become a mature protein. The cleaved region is referred to as intein, and the region remaining as the mature protein is referred to as extein.

[0041] In one embodiment, the split inteins are nostock punctiformes ( Nostoc punctiforme It may be a DNA E protein derived from ).

[0042] In one embodiment, the carboxyl terminal fragment of the split intein may include the amino acid sequence of SEQ ID NO. 9 and may be encoded by the base sequence of SEQ ID NO. 18.

[0043] In one embodiment, the amino-terminal fragment of the split intein may include the amino acid sequence of SEQ ID NO. 10 and may be encoded by the base sequence of SEQ ID NO. 19.

[0044] In one embodiment, in a fusion protein translated by the recombinant expression vector of the present invention, the entain formed by combining the N-terminal fragment of a split entain and the C-terminal fragment of an entain is removed, thereby fusing both ends of a growth factor, its fragment, or its variant, so that the growth factor, its fragment, or its variant may be cyclic.

[0045] In one aspect, the present invention relates to a recombinant expression vector comprising a sequence encoding a fragment of FGF10 (fibroblast growth factor) or a variant thereof.

[0046] In one embodiment, the recombinant expression vector may encode the fusion protein of SEQ ID NO. 21 and may include the nucleotide sequence of SEQ ID NO. 22.

[0047] In one embodiment, the recombinant expression vector may encode the fusion protein of SEQ ID NO. 24, 26, or 28 and may include the nucleotide sequence of SEQ ID NO. 23, 25, or 27.

[0048] In one embodiment, FGF10 may include any one selected from the group consisting of amino acid sequences of SEQ ID NOs 1 to 3, and the FGF10 may include any one selected from the group consisting of nucleotide sequences of SEQ ID NOs 13 to 15.

[0049] In one embodiment, the fragment of FGF10 may include the amino acid sequence of SEQ ID NO. 4 or 5, and the fragment of FGF10 may include the nucleotide sequence of SEQ ID NO. 16 or 17.

[0050] In one embodiment, a variant of FGF10 may include one or more amino acid substitutions selected from the group consisting of A133C, Y177C and A199C, and a vector of the present invention may include any one nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID NOs 6 to 8.

[0051] In one embodiment, the recombinant expression vector of the present invention comprising a sequence encoding a fragment of FGF10 or a variant thereof may increase the production efficiency of FGF10 protein compared to a vector comprising a sequence encoding wild-type FGF10.

[0052] In one embodiment, a fragment of FGF10 or a variant thereof produced by the expression vector of the present invention may be a linear protein.

[0053] In the present invention, variants of FGF10 of the present invention are defined according to amino acid modifications constituting FGF10, and the term "amino acid modification / variant" as used in the present invention refers to the substitution, insertion, and / or deletion of amino acids in a protein sequence, preferably substitution. The term "amino acid substitution" or "substitution" as used in the present invention refers to the replacement of an amino acid at a specific position in the polypeptide sequence of wild-type FGF10 with another amino acid.

[0054] As used herein, the term "variant of FGF10" means comprising a modification of one or more amino acid residues compared to wild-type FGF10.

[0055] In one embodiment, the vector may include a sequence encoding a fusion protein in which a carboxyl terminal (C-term) fragment of intein is fused to the amino terminal (N-term) of FGF10, a fragment thereof, or a variant thereof, and an amino terminal fragment of intein is fused to the carboxyl terminal of FGF10, a fragment thereof, or a variant thereof.

[0056] In one embodiment, the recombinant expression vector can make the distance between the N-terminus and C-terminus of FGF10, its fragment, or its variant 6 to 20 Å, and said distance is an optimal distance condition for the cyclicization of FGF10, its fragment, or its variant.

[0057] In one embodiment, the recombinant expression vector may be for producing cyclic FGF10, a cyclic FGF10 fragment, or a cyclic FGF10 variant.

[0058] In one embodiment, the recombinant expression vector may include a tag sequence, and the tag may be a His tag, a Myc(c-myc) tag, a FLAG tag, a HA tag, or a T7 tag, and is more preferably a His tag.

[0059] In one embodiment, the recombinant expression vector may additionally include a nucleotide sequence encoding a linker between FGF10, a fragment thereof or a variant thereof and a fragment of intane, and the linker may include the amino acid sequence GGSGGS of SEQ ID NO. 11, thereby increasing the cyclicity efficiency of FGF10, a fragment thereof or a variant thereof.

[0060] In one embodiment, the recombinant expression vector may additionally include a base sequence encoding three amino acid residues between the carboxyl terminus of the split integrin and the linker, and it is preferable that the three amino acid residues be CFN (Sequence No. 12) as this optimizes the production efficiency of the most cyclic FGF10, its fragments, or its variants.

[0061] In one embodiment, the fusion protein translated by the recombinant expression vector may also include a targeting sequence, a tag, a labeled residue, a half-life, or an additional amino acid sequence designed for a specific purpose to increase the stability of the peptide.

[0062] In one embodiment, the fusion protein translated by the recombinant expression vector may further include a fluorescent protein, and the fluorescent protein may be a green fluorescent protein (GFP), an enhanced green fluorescent protein (EGFP), a yellow fluorescent protein (YFP), a red fluorescent protein (RFP), an orange fluorescent protein (OFP), a cyan fluorescent protein (CFP), a blue fluorescent protein (BFP), a far-red fluorescent protein, or a tetracysteine ​​motif.

[0063] In one embodiment, the expression vector may comprise a protein that is functionally related, i.e., operably linked with a regulatory or regulatory sequence, a selection marker, any fusion partner, and / or additional elements.

[0064] In the present invention, the terms "peptide," "polypeptide," and "protein" may be used interchangeably.

[0065] The term "peptide" as used in the present invention refers to an amino acid polymer that may include not only natural amino acids but also non-protein amino acids as components.

[0066] In the present invention, the recombinant expression vector can typically be constructed as a vector for expression. In particular, considering the convenience of culture, it is preferable to use a prokaryotic cell as the host cell. Furthermore, such an expression vector may further include a promoter that regulates the expression of the encoded protein. The promoter generally includes a potent promoter capable of proceeding transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter, etc.), a ribosome binding site for initiating translation, and a transcription / translation termination sequence. Additionally, as a host cell E. coli When used, E. coli The promoter and operator sites of the tryptophan biosynthetic pathway and the left-handed promoter of phage λ (pLλ promoter) can be used as regulatory sites.

[0067] Meanwhile, vectors that can be used in the present invention may be produced by manipulating plasmids (e.g., pSC101, pET29b, ColE1, pBR322, pUC8 / 9, pHC79, pUC19, pET, etc.) commonly used in the art, phages (e.g., λgt4λB, λ-Charon, λΔz1 and M13, etc.), or viruses (e.g., SV40, etc.), but are not limited thereto. Most preferably, pET29b, which has a bacteriophage T7 promoter and whose protein expression is induced by IPTG (Isopropyl β-D-1-thiogalactopyranoside), may be used.

[0068] According to one embodiment of the present invention, a transformant can be obtained by transforming a host cell with the recombinant expression vector. Since the transformant is a strain capable of expressing the recombinant expression vector, it is defined herein as a strain that produces a circular protein. Any host cell known in the art may be used to obtain the production strain of the present invention, for example, E. coli JM109, E. coli BL21(DE3), E. coli BL21(DE3) pLysS, E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, E. coli W3110, E. coli Bacillus strains such as Rosetta(DE3)pLysS, Bacillus subtilis, and Bacillus churingensis, as well as intestinal bacteria and strains such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species, may be used, but Rosetta(DE3)pLysS and BL21(DE3)pLysS are more preferred, though not limited thereto.

[0069] Methods for transporting vectors, etc. into host cells during the transformation process include the CaCl2 method (Cohen, SN et al., Proc. Natl. Acac. Sci. USA, 9:2110-2114(1973)), the Hanahan method (Cohen, SN et al., Proc. Natl. Acac. Sci. USA, 9:2110-2114(1973); and Hanahan, D., J. Mol. Biol., 166:557-580(1983)) and the electroporation method (Dower, WJ et al., Nucleic. Acids Res., 16:6127-6145(1988)).

[0070] In one embodiment, the cFGF10 protein of the present invention may be produced by a production method comprising the steps of: culturing the above-mentioned transformant and inducing protein expression; separating and purifying the protein using affinity for heparin; separating and purifying the protein using a cation exchange column; and separating and purifying the protein using a nickel column.

[0071] In one embodiment, the step of separating and purifying proteins with a nickel column may be performed using Ni-NTA that binds to a histidine (His) tag, wherein the Ni-NTA is a resin that binds to a histidine tag, more specifically, Ni used for the purification of cyclic proteins 2+ It is a -charged agarose, and the purification step using Ni-NTA can be appropriately performed by a person skilled in the art according to conventional methods used in the relevant technical field.

[0072] In one embodiment, in the step of culturing the transformant, the culture conditions of the transformant may vary depending on the type of transformed host cell, but it is preferable that the temperature be 25 to 40°C.

[0073] In one embodiment, the conditions for inducing protein expression in the transformant may be a temperature of 13 to 17°C and treatment with 0.3 to 0.7 mM IPTG.

[0074] In one embodiment, a cyclic fibroblast growth factor 10 protein can be produced by the steps of: culturing a transformant transformed with the expression vector and inducing protein expression; isolating and purifying the protein using affinity for heparin; isolating and purifying the protein using a cation exchange column; and isolating and purifying the protein using a nickel column.

[0075] In one embodiment, the transformant may be E. coli.

[0076] In one embodiment, the step of separating and purifying proteins with a nickel column may be performed using Ni-NTA that binds to a histidine (His) tag, wherein the Ni-NTA is a resin that binds to a histidine tag, more specifically, Ni used for the purification of cyclic proteins 2+ It is a -charged agarose, and the purification step using Ni-NTA can be appropriately performed by a person skilled in the art according to conventional methods used in the relevant technical field.

[0077] In one embodiment, in the step of culturing the transformant, the culture conditions of the transformant may vary depending on the type of transformed host cell, but it is preferable that the temperature be 25 to 40°C.

[0078] In one embodiment, the conditions for inducing protein expression in the transformant may be a temperature of 13 to 17°C and treatment with 0.3 to 0.7 mM IPTG.

[0079] In one aspect, the present invention relates to a method for producing fibroblast growth factor 10, a fragment thereof, or a variant thereof, comprising the steps of: culturing a transformant of the present invention and inducing protein expression; separating and purifying the protein using an affinity for heparin; separating and purifying the protein using a nickel column (Ni-NTA); and separating and purifying the protein using cation exchange chromatography.

[0080] In one embodiment, the fibroblast growth factor 10, a fragment thereof, or a variant thereof may be cyclic.

[0081] In one embodiment, the cyclic protein of the present invention may be formed by connecting both ends of FGF10, a fragment thereof, or a variant thereof, by removing the phosphate formed by combining the N-terminal fragment of phosphate and the C-terminal fragment of phosphate of a fusion protein translated by the recombinant expression vector of the present invention.

[0082] In the present invention, the cyclic FGF10 can be prepared in the form of a pharmaceutically acceptable salt. Specifically, the salt can be formed by adding an acid, for example, by adding an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), an organic carboxylic acid (e.g., acetic acid, haloacetic acid such as trifluoroacetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), an acidic sugar (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), an acidic polysaccharide (e.g., hyaluronic acid, chondroitin sulfate, arginine acid), an organic sulfonic acid including a sulfonic acid sugar ester such as chondroitin sulfate (e.g., methanesulfonic acid, p-toluenesulfonic acid), etc.

[0083] In one aspect, the present invention relates to a composition for promoting cell proliferation comprising the annular fibroblast growth factor 10 of the present invention.

[0085] The present invention will be explained in more detail through the following examples. However, the following examples are intended only to illustrate the content of the present invention and do not limit the present invention.

[0087] Example 1. Expression and purification of full-length FGF10 expression vector

[0088] Expression vectors (Fig. 1) containing genes encoded by human FGF10 (Human Fibroblast growth factors 10, hFGF10) (Sequence No. 1), minke whale FGF10 (Minke whale Fibroblast growth factors 10, W1FGF10) (Sequence No. 2), and killer whale FGF10 (Killer whale Fibroblast growth factors 10, W2FGF10) (Sequence No. 3), respectively, were transformed into rosetta (DE3) pLysS cells and expressed under conditions of 0.5 mM IPTG and 15°C. Subsequently, in step 1, the proteins were separated and purified using affinity for heparin to confirm bands of the predicted size of the three types of FGF10 proteins on SDS-PAGE, and in step 2, the proteins were purified using cation exchange chromatography to obtain three types of full-length FGF10 proteins excluding the purely isolated signal peptide (Fig. 2).

[0090] Example 2. Expression and purification of FGF10 fragment expression vector

[0091] Since the FR (flexible region) or the FR and α1 regions of FGF10 were expected to be disadvantageous for crystallization, genes encoding a human FGF10 protein fragment with the FR removed (SEQ No. 4) and a human FGF10 protein fragment with the FR and α1 regions removed (SEQ No. 5) were cloned into vectors, respectively, expressed in E. coli as in Example 1 above, and purified in two steps. During the two-step purification process, bands of predicted sizes of three types of FGF10 proteins (full-length hFGF10 excluding signal protein, hFGF10 with the FR removed, and hFGF10 with the FR and α1 regions removed) were identified on SDS-PAGE after separation and purification using affinity for heparin, confirming that each protein was stably expressed and produced (Fig. 3).

[0093] Example 3. Expression and purification of an FGF10 variant expression vector with increased stability

[0094] In order to promote proper folding of the FGF10 protein and stabilize its tertiary and quaternary structures, expression vectors were created by cloning genes (sequence numbers 6 to 8, respectively) encoding variants A133C, Y177C / A199C and A133C / Y177C / A199C, in which a portion of the FGF10 sequence was substituted with a cysteine ​​residue to induce disulfide bonding. These vectors were expressed in E. coli as in Example 1 above and purified in two steps.

[0095] As a result, it was confirmed that FGF10 variants were expressed and purified (Fig. 4). When a protein is produced using a vector encoding the FGF10 variant, the unfolding of the FGF10 protein can be prevented, and the FGF10 variant thus prepared has thermal stability, which maintains the structure and activity of the protein at high temperatures, and chemical stability, which protects the FGF10 protein from chemical degradation such as oxidation and reduction that can alter the structure and activity of the protein.

[0097] Example 4. Establishment of a Cyclic FGF10 Protein Production System

[0098] 4-1. Construction of a Vector for cFGF10 Protein Production

[0099] To increase the in vivo stability (half-life) of the FGF10 protein, to produce FGF10 in a cyclic form using a bacterial expression system, promoter, start codon, His-tag, Npu Split intein carboxyl-terminal (C-term) fragment of DnaE (6.5 kDa) (Sequence No. 9), restriction enzyme recognition site of BamHI, restriction enzyme recognition site of EcoRI, Npu A gene sequence (Fig. 5) encoding an FGF10 protein (17.8 kDa), with codons optimized for E. coli expression as an example of the target protein, was inserted at the restriction enzyme BamHⅠ and EcoRⅠ positions of the Multi-cloning Site (MCS) of a pET29b vector (INTEIN_pET29b vector) containing a DnaE split intein amino-terminal (N-term) fragment (11.7 kDa) (SEQ No. 10) and a T7 promoter containing a stop codon (Fig. 6). When the vector is expressed in a cell, the two split intein portions (C-term and N-term portions) at both ends of the expressed full-length protein form a complex and fold into a normal intein, thereby performing the circularization of the inserted FGF10, and the circularized FGF10 (cFGF10) detaches from the split intein enzyme to produce a circular protein (Fig. 7).

[0101] 4-2. Expression and Purification of cFGF10

[0102] When the vector prepared in Example 4-1 above is expressed in BL21(DE3) pLysS cells under conditions of 0.5 mM IPTG and 15°C, the gene encoding FGF10 is expressed as a soluble protein within the cell in a form in which three parts—an intein C-terminal portion, the FGF10 gene, and a split intein N-terminal—are sequentially connected with a His-tag at the N-terminal, and the FGF10 protein is cyclicized by split intein activity within the cell. Proteins produced in E. coli were first isolated and purified using a heparin column to which FGF10 has affinity, separating proteins containing the FGF10 portion; secondly, they were further purified using a cation exchange column; and thirdly, the full-length proteins were removed using a Ni-NTA column to finally isolate and purify only the cyclic FGF10 proteins that were not bound to the column (Fig. 8). The band sizes of the proteins isolated and purified at each step were then examined on SDS-PAGE (Fig. 9). As a result, it was found that approximately 20% of the total expressed proteins were cyclic (left diagram of Figs. 10 and 11).

[0104] Example 5. Improved cyclic FGF10 protein production system

[0105] To improve the cyclic efficiency of the FGF10 protein, a linker was inserted at the junction site between the two domain sequences of the split integrin in the vector and the sequence of the gene encoding the target protein, and the improvement in the cyclic efficiency of FGF10 was confirmed according to the length and sequence of the linker (Fig. 12). At this time, the three amino acid sequence that exists between the C-terminus of the integrinus and the linker due to the inclusion of the linker is CGS, where C is a sequence that is necessarily included because the N-terminus and C-terminus of the target protein are connected by a disulfide bond, and GS is an extra residue derived from BamH1.

[0106] As a result, the cyclic efficiency of FGF10 varied depending on the sequence and length of the linker inserted at the junction site between the split entain and the target protein, and the cyclic efficiency of FGF10 was found to be highest when a 6-amino acid sequence (GGSGGS) (Sequence No. 11) was inserted into the N-term and C-term of the target protein, respectively.

[0107] Through this, it was confirmed that for annulation through the connection of the N-terminus and C-terminus of FGF10, the two ends must be located close together (within approximately 13 Å), and that the annulation efficiency of FGF10 increases to approximately 30% when GGSGGS, a flexible linker, is present at the N-terminus and C-terminus of FGF10, respectively (middle diagram of Fig. 11).

[0109] Example 6. Optimized Cyclic FGF10 Protein Production System

[0110] To improve the cyclic efficiency of the FGF10 protein, the vector was modified to encode a fusion protein (SEQ No. 21) (Fig. 13) in which the three amino acid sequence CGS located between the C-terminus of the phosphate group and the linker GGSGGS was changed to CFN (SEQ No. 12) (Fig. 14 and 15) (SEQ No. 22) (Fig. 16). When the target protein was expressed and confirmed, it was found that no intermediate protein products that were not cyclic were obtained, and 100% of the protein was cyclic (right diagram of Fig. 11).

[0112] Example 7. Verification of cyclic formation of cyclic FGF10 protein

[0113] Among the various human FGF10 constructs described in FIG. 19 that were prepared in the above examples, FGF10_E (SEQ Nos. 23 and 24), FGF10_C (SEQ Nos. 25 and 26), and FGF10*_C (FGF10_C including mutations) were cyclicized and expressed and purified after optimizing the linker and additional amino acid sequences as in Example 6, and the cyclicization was verified by confirming the portion where the N-term and C-term of the cFGF10 protein are connected by a peptide bond using Mass Spectroscopy MS / MS.

[0114] As a result, various human FGF10 protein constructs with optimized linkers and additional amino acids were confirmed to be successfully cyclic (Fig. 17).

[0116] Example 8. Confirmation of cell proliferation activity of cyclic FGF10 protein

[0117] To analyze the cellular activity of the isolated and purified cyclic proteins, the cell proliferation activity of linear FGF10 proteins (hFGF10-new; hFGF10-old; and FGF10 mt3: A133C, Y177C, and A199C variants) and cyclic FGF10 proteins (cFGF10 and cFGF10-1) was examined. As a result, cFGF10 showed cell proliferation activity similar to that of the normal linear FGF10 (Fig. 18). Therefore, it was confirmed that the cyclic cFGF10 protein is active.

Claims

Claim 1 A cyclic fibroblast growth factor 10 characterized by having a cyclic structure in which an amino terminus and a carboxyl terminus are connected by a peptide bond and maintaining cell proliferation activity corresponding to linear fibroblast growth factor 10, wherein the cyclic fibroblast growth factor 10 comprises an amino acid sequence encoded by any one of SEQ ID NOs 1 to 3, the amino acid sequence of SEQ ID NO. 4 or 5, or a nucleotide sequence of any one of SEQ ID NOs 6 to 8. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 In claim 1, the amino acid sequence encoded by any one of the base sequences of SEQ ID NOs 6 to 8 comprises one or more amino acid substitutions selected from the group consisting of A133C, Y177C, and A199C, cyclic fibroblast growth factor 10. Claim 7 delete Claim 8 In claim 1, the annular fibroblast growth factor 10 is an annular fibroblast growth factor 10 having an increased half-life in vivo compared to linear fibroblast growth factor 10. Claim 9 delete Claim 10 A composition for promoting cell proliferation comprising the cyclic fibroblast growth factor 10 of claim 1. Claim 11 A recombinant expression vector for producing cyclic fibroblast growth factor 10, comprising a sequence encoding fibroblast growth factor 10 including an amino acid sequence of any one of SEQ ID NOs 1 to 3, an amino acid sequence of SEQ ID NOs 4 or 5, or a nucleotide sequence of any one of SEQ ID NOs 6 to 8, wherein a carboxyl terminal (C-term) fragment of intein is fused to the amino terminal (N-term) of fibroblast growth factor 10, and configured to express a fusion protein in which the amino terminal (N-term) fragment of intein is fused to the carboxyl terminal (C-term) of fibroblast growth factor 10, and designed such that the distance between the N-termin and C-termin of fibroblast growth factor 10 is in the range of 6 to 20 Å. Claim 12 delete Claim 13 delete Claim 14 In claim 11, the recombinant expression vector wherein the amino acid sequence encoded by any one of the base sequences of SEQ ID NOs 6 to 8 comprises one or more amino acid substitutions selected from the group consisting of A133C, Y177C, and A199C. Claim 15 delete Claim 16 In claim 11, the recombinant expression vector is configured to increase protein production efficiency compared to a vector containing a sequence encoding full-length fibroblast growth factor 10. Claim 17 delete Claim 18 delete Claim 19 In claim 11, the carboxyl terminal fragment of the intein comprises the amino acid sequence of SEQ ID NO. 9, in a recombinant expression vector. Claim 20 In claim 11, the amino-terminal fragment of the intein comprises the amino acid sequence of SEQ ID NO. 10, in a recombinant expression vector. Claim 21 delete Claim 22 A recombinant expression vector according to claim 11, further comprising a base sequence encoding a linker between the amino terminus of fibroblast growth factor 10 and a fragment of phosphate or between the carboxy terminus of fibroblast growth factor 10 and a fragment of phosphate. Claim 23 In claim 22, the recombinant expression vector is one in which the linker is composed of the amino acid sequence of SEQ ID NO.

11. Claim 24 A recombinant expression vector according to claim 22, further comprising a base sequence encoding an amino acid residue CFN between the carboxyl terminus of the intein and the linker. Claim 25 A transgenic body other than a human, transformed with a recombinant expression vector according to any one of claims 11, 14, 16, 19, 20, and 22 through 24. Claim 26 A method for producing cyclic fibroblast growth factor 10, comprising: a) culturing the transformant of claim 25 and inducing protein expression; b) separating and purifying the protein using affinity for heparin; c) separating and purifying the protein using a nickel column (Ni-NTA); and d) separating and purifying the protein using cation exchange chromatography. Claim 27 delete

Citation Information

Patent Citations

  • Novel cyclic peptide, manufacturing method of the same anc use of the same

    KR1020200048668A

  • Fibroblast Growth Factor-10

    US20050019824A1